1. | brianpitkin | |
2. | reformed4553 | |
3. | edesedyjy69fed | |
4. | andersenj182 | |
5. | mlaura |
1. | brianpitkin | |
2. | reformed4553 | |
3. | edesedyjy69fed | |
4. | andersenj182 | |
5. | mlaura |
1. | brianpitkin 01/26/2018 Company announced that new interim results from its ongoing Phase 1 clinical trial of MRG-106 in patients wi… |
2. | edesedyjy69fed 02/05/2018 perfect day for it, everything is dying |
3. | brianpitkin 02/05/2018 miRagen Therapeutics Announces Proposed Public Offering of Common Stock |
4. | edesedyjy69fed 02/08/2018 Prices 7 mln share common stock offering at $5.50 per share |
5. | reformed4553 02/05/2018 {Image} |
6. | edesedyjy69fed 02/02/2018 Nice News out - miRagen Therapeutics Presents New Data from Phase 1 Clinical Trial of MRG-106 in Mycosis Fungoides at the T-Cell Lymphoma Forum |
7. | brianpitkin 04/27/2018 miRagen Therapeutics Announces New Data Showing Administration of MRG-110 Improved Tissue Perfusion and Wound Healing in Late Stage Preclinical Studies |